The pathogenic roles of B cells in autoimmune diseases occur through several mechanistic
pathways that include autoantibodies, immune complexes, dendritic and T cell activation …

The pathogenic roles of B cells in human autoimmune diseases involve a multitude of
mechanistic pathways and include the well-established contributions of autoantibodies and …

The advent of therapies that specifically target the B‐lymphocyte lineage in human disease
has rejuvenated interest in the mechanistic biology by which B cells mediate autoimmunity …

Purpose of review FDA-approved B cell-targeted therapy has expanded to a multitude of
autoimmune diseases ranging from organ specific diseases, like pemphigus and multiple …

The successful use of B cell depletion therapy for the treatment of autoimmune disease has
led to a resurgent appreciation of B cells as powerful regulators of immunity. However, to the …

Autoimmunity results from abnormal B‐and T‐cell recognition of self‐antigens, which leads
to autoantibody production in many cases. Autoantibodies produced by B‐cell‐derived …

Recent advances have led to the development of mAbs that effectively deplete B cells in
human beings and target pathways essential for B-cell development. B cell–directed …

The role of B cells in autoimmune diseases involves different cellular functions, including the
well‐established secretion of autoantibodies, autoantigen presentation and ensuing …

B cells are classically considered solely as antibody-producing cells driving humoral
immune responses to foreign antigens in infections and vaccinations as well as self …

Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …